Skip to main content
Top
Published in: BMC Infectious Diseases 1/2010

Open Access 01-12-2010 | Research article

Can vaccinia virus be replaced by MVA virus for testing virucidal activity of chemical disinfectants?

Authors: Holger F Rabenau, Ingrid Rapp, Jochen Steinmann

Published in: BMC Infectious Diseases | Issue 1/2010

Login to get access

Abstract

Background

Vaccinia virus strain Lister Elstree (VACV) is a test virus in the DVV/RKI guidelines as representative of the stable enveloped viruses. Since the potential risk of laboratory-acquired infections with VACV persists and since the adverse effects of vaccination with VACV are described, the replacement of VACV by the modified vaccinia Ankara strain (MVA) was studied by testing the activity of different chemical biocides in three German laboratories.

Methods

The inactivating properties of different chemical biocides (peracetic acid, aldehydes and alcohols) were tested in a quantitative suspension test according to the DVV/RKI guideline. All tests were performed with a protein load of 10% fetal calf serum with both viruses in parallel using different concentrations and contact times. Residual virus was determined by endpoint dilution method.

Results

The chemical biocides exhibited similar virucidal activity against VACV and MVA. In three cases intra-laboratory differences were determined between VACV and MVA - 40% (v/v) ethanol and 30% (v/v) isopropanol are more active against MVA, whereas MVA seems more stable than VACV when testing with 0.05% glutardialdehyde. Test accuracy across the three participating laboratories was high. Remarkably inter-laboratory differences in the reduction factor were only observed in two cases.

Conclusions

Our data provide valuable information for the replacement of VACV by MVA for testing chemical biocides and disinfectants. Because MVA does not replicate in humans this would eliminate the potential risk of inadvertent inoculation with vaccinia virus and disease in non-vaccinated laboratory workers.
Appendix
Available only for authorised users
Literature
1.
go back to reference CDC: Supplement: collected recommendations of the Public Health Service Advisory Committee on Immunization Practices. MMWR. 1972, 2: 1- CDC: Supplement: collected recommendations of the Public Health Service Advisory Committee on Immunization Practices. MMWR. 1972, 2: 1-
2.
go back to reference Breman JG, Arita I: The confirmation and maintenance of smallpox eradication. N Engl J Med. 1980, 303 (22): 1263-73.CrossRefPubMed Breman JG, Arita I: The confirmation and maintenance of smallpox eradication. N Engl J Med. 1980, 303 (22): 1263-73.CrossRefPubMed
3.
go back to reference CDC: Recommendations for using smallpox vaccine in a pre-event vaccination program: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR. 2003, 52 (RR-7): CDC: Recommendations for using smallpox vaccine in a pre-event vaccination program: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR. 2003, 52 (RR-7):
4.
go back to reference Mayr A, Stickl H, Müller HK, Danner K, Singer H: The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism. Zbl Bakt Hyg I Abt Orig B. 1978, 167: 375-390. Mayr A, Stickl H, Müller HK, Danner K, Singer H: The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism. Zbl Bakt Hyg I Abt Orig B. 1978, 167: 375-390.
5.
go back to reference Stittelaar KJ, Kuiken T, de Swart RL, van Amerongen G, Vos HW, Niesters HG, van Schalkwijk P, van der Kwast T, Wyatt LS, Moss B, Osterhaus AD: Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine. 2001, 19 (27): 3700-3709. 10.1016/S0264-410X(01)00075-5.CrossRefPubMed Stittelaar KJ, Kuiken T, de Swart RL, van Amerongen G, Vos HW, Niesters HG, van Schalkwijk P, van der Kwast T, Wyatt LS, Moss B, Osterhaus AD: Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine. 2001, 19 (27): 3700-3709. 10.1016/S0264-410X(01)00075-5.CrossRefPubMed
6.
go back to reference EN 14476: Chemical disinfectants and antiseptics. Virucidal quantitative suspension test for chemical disinfectants and antiseptics used in human medicine. Test method and requirements (phase 2, step 1). 2007 EN 14476: Chemical disinfectants and antiseptics. Virucidal quantitative suspension test for chemical disinfectants and antiseptics used in human medicine. Test method and requirements (phase 2, step 1). 2007
7.
go back to reference Blümel J, Glebe D, Neumann-Haefelin D, Rabenau HF, Rapp I, von Rheinbaben F, Ruf B, Sauerbrei A, Schwebke I, Steinmann J, Willkommen H, Wolff MH, Wutzler P: Guideline of "Deutsche Vereinigung zur Bekämpfung der Viruskrankheiten e.V." (DVV; German Association for the Control of Virus Diseases) and Robert Koch-Institute (RKI; German Federal Health Authority) for testing the virucidal efficacy of chemical disinfectants in the human medical area. Hyg Med. 2009, 34 (7/8): 293-299. Blümel J, Glebe D, Neumann-Haefelin D, Rabenau HF, Rapp I, von Rheinbaben F, Ruf B, Sauerbrei A, Schwebke I, Steinmann J, Willkommen H, Wolff MH, Wutzler P: Guideline of "Deutsche Vereinigung zur Bekämpfung der Viruskrankheiten e.V." (DVV; German Association for the Control of Virus Diseases) and Robert Koch-Institute (RKI; German Federal Health Authority) for testing the virucidal efficacy of chemical disinfectants in the human medical area. Hyg Med. 2009, 34 (7/8): 293-299.
8.
go back to reference Anonymous: Prüfung und Deklaration der Wirksamkeit von Desinfektionsmitteln gegen Viren. Stellungnahme des Arbeitskreises Viruzidie beim Robert Koch-Institut (RKI) sowie des Fachausschusses Virusdesinfektion der Deutschen Gesellschaft zur Bekämpfung der Viruskrankheiten (DVV) und der Desinfektionsmittelkommission der Deutschen Gesellschaft für Hygiene und Mikrobiologie (DGHM). Bundesgesundhbl. 2004, 47 (1): 62-66. 10.1007/s00103-003-0754-7.CrossRef Anonymous: Prüfung und Deklaration der Wirksamkeit von Desinfektionsmitteln gegen Viren. Stellungnahme des Arbeitskreises Viruzidie beim Robert Koch-Institut (RKI) sowie des Fachausschusses Virusdesinfektion der Deutschen Gesellschaft zur Bekämpfung der Viruskrankheiten (DVV) und der Desinfektionsmittelkommission der Deutschen Gesellschaft für Hygiene und Mikrobiologie (DGHM). Bundesgesundhbl. 2004, 47 (1): 62-66. 10.1007/s00103-003-0754-7.CrossRef
9.
go back to reference Anonymous: Richtlinien zur Prüfung chemischer Desinfektionsmittel für die Veterinärmedizin. Deutsche Veterinärmedizinische Gesellschaft e. V., Gießen. 2000 Anonymous: Richtlinien zur Prüfung chemischer Desinfektionsmittel für die Veterinärmedizin. Deutsche Veterinärmedizinische Gesellschaft e. V., Gießen. 2000
10.
go back to reference Auckland C, Cowlishaw A, Morgan D, Miller E: Reactions to small pox vaccine in naïve and previously-vaccinated individuals. Vaccine. 2005, 23: 4185-4187. 10.1016/j.vaccine.2004.10.052.CrossRefPubMed Auckland C, Cowlishaw A, Morgan D, Miller E: Reactions to small pox vaccine in naïve and previously-vaccinated individuals. Vaccine. 2005, 23: 4185-4187. 10.1016/j.vaccine.2004.10.052.CrossRefPubMed
11.
go back to reference Eckart RE, Shry EA, Jones SO, Atwood JE, Grabenstein JD: Comparison of clinical presentation of acute myocarditis following smallpox vaccination to acute coronary syndromes in patients <40 years of age. Am J Cardiol. 2005, 95 (10): 1252-1255. 10.1016/j.amjcard.2005.01.061.CrossRefPubMed Eckart RE, Shry EA, Jones SO, Atwood JE, Grabenstein JD: Comparison of clinical presentation of acute myocarditis following smallpox vaccination to acute coronary syndromes in patients <40 years of age. Am J Cardiol. 2005, 95 (10): 1252-1255. 10.1016/j.amjcard.2005.01.061.CrossRefPubMed
12.
go back to reference Sejvar JJ, Labutta RK, Chapman LE, Grabenstein JD, Iskander J, Lane JM: Neurologic adverse events associated with smallpox vaccination in the United States, 2002-2004. JAMA. 2005, 294 (21): 2744-2750. 10.1001/jama.294.21.2744.CrossRefPubMed Sejvar JJ, Labutta RK, Chapman LE, Grabenstein JD, Iskander J, Lane JM: Neurologic adverse events associated with smallpox vaccination in the United States, 2002-2004. JAMA. 2005, 294 (21): 2744-2750. 10.1001/jama.294.21.2744.CrossRefPubMed
13.
go back to reference CDC: Surveillance guidelines for smallpox vaccine (vaccinia) adverse reactions. MMWR. 2006, 55 (RR-1): CDC: Surveillance guidelines for smallpox vaccine (vaccinia) adverse reactions. MMWR. 2006, 55 (RR-1):
14.
go back to reference CDC: Laboratory-acquired vaccinia exposures and infections---United States, 2005--2007. MMWR. 2008, 57: 401-404. CDC: Laboratory-acquired vaccinia exposures and infections---United States, 2005--2007. MMWR. 2008, 57: 401-404.
15.
go back to reference Lewis FM, Chernak E, Goldman E, Li Y, Karem K, Damon IK, Henkel R, Newbern EC, Ross P, Johnson CC: Ocular vaccinia infection in laboratory worker, Philadelphia, 2004. Emerg Infect Dis. 2006, 12: 134-137.CrossRefPubMedPubMedCentral Lewis FM, Chernak E, Goldman E, Li Y, Karem K, Damon IK, Henkel R, Newbern EC, Ross P, Johnson CC: Ocular vaccinia infection in laboratory worker, Philadelphia, 2004. Emerg Infect Dis. 2006, 12: 134-137.CrossRefPubMedPubMedCentral
16.
go back to reference Mempel M, Isa G, Klugbauer N, Meyer H, Wildi G, Ring J, Hofmann F, Hofmann H: Laboratory acquired infection with recombinant vaccinia virus containing an immunomodulating construct. J Invest Dermatol. 2003, 120 (3): 356-358. 10.1046/j.1523-1747.2003.12074.x.CrossRefPubMed Mempel M, Isa G, Klugbauer N, Meyer H, Wildi G, Ring J, Hofmann F, Hofmann H: Laboratory acquired infection with recombinant vaccinia virus containing an immunomodulating construct. J Invest Dermatol. 2003, 120 (3): 356-358. 10.1046/j.1523-1747.2003.12074.x.CrossRefPubMed
17.
go back to reference Openshaw PJM, Alwan WH, Cherrie AH, Record FM: Accidental infection of laboratory worker with recombinant vaccinia virus. Lancet. 1991, 338: 459-10.1016/0140-6736(91)91093-A.CrossRefPubMed Openshaw PJM, Alwan WH, Cherrie AH, Record FM: Accidental infection of laboratory worker with recombinant vaccinia virus. Lancet. 1991, 338: 459-10.1016/0140-6736(91)91093-A.CrossRefPubMed
18.
go back to reference Rupprecht CE, Blass L, Smith K, Orciari LA, Niezgoda M, Whitfield SG, Gibbons RV, Guerra M, Hanlon CA: Human infection due to recombinant vaccinia-rabies glycoprotein virus. N Engl J Med. 2001, 345: 582-586. 10.1056/NEJMoa010560.CrossRefPubMed Rupprecht CE, Blass L, Smith K, Orciari LA, Niezgoda M, Whitfield SG, Gibbons RV, Guerra M, Hanlon CA: Human infection due to recombinant vaccinia-rabies glycoprotein virus. N Engl J Med. 2001, 345: 582-586. 10.1056/NEJMoa010560.CrossRefPubMed
19.
go back to reference Wlodaver CG, Palumbo GJ, Waner JL: Laboratory-acquired vaccinia infection. J Clin Virol. 2004, 29: 167-170. 10.1016/S1386-6532(03)00118-5.CrossRefPubMed Wlodaver CG, Palumbo GJ, Waner JL: Laboratory-acquired vaccinia infection. J Clin Virol. 2004, 29: 167-170. 10.1016/S1386-6532(03)00118-5.CrossRefPubMed
20.
go back to reference CDC: Laboratory-Acquired Vaccinia Virus Infection - Virginia, 2008. MMWR. 2009, 58 (29): 797-800. CDC: Laboratory-Acquired Vaccinia Virus Infection - Virginia, 2008. MMWR. 2009, 58 (29): 797-800.
21.
go back to reference Hartnack S, Essbauer S, Truyen U: Substitution of vaccinia virus Elstree by modified vaccinia virus Ankara to test the virucidal efficacy of chemical disinfectants. Zoonoses Public Health. 2008, 55 (2): 99-105.CrossRefPubMed Hartnack S, Essbauer S, Truyen U: Substitution of vaccinia virus Elstree by modified vaccinia virus Ankara to test the virucidal efficacy of chemical disinfectants. Zoonoses Public Health. 2008, 55 (2): 99-105.CrossRefPubMed
22.
go back to reference Spearman C: The method of "right and wrong cases" ("constant stimuli") without Gauss's formulae. British Journal of Psychology. 1908, 2: 227-242. Spearman C: The method of "right and wrong cases" ("constant stimuli") without Gauss's formulae. British Journal of Psychology. 1908, 2: 227-242.
23.
go back to reference Kaerber G: Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch Exp Path Pharmako. 1931, 162: 480-483. 10.1007/BF01863914.CrossRef Kaerber G: Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch Exp Path Pharmako. 1931, 162: 480-483. 10.1007/BF01863914.CrossRef
25.
go back to reference Kemper A, Davis M, Freed G: Expected adverse events in a mass smallpox vaccination campaign. Effect Clin Pract. 2002, 5: 84-90. Kemper A, Davis M, Freed G: Expected adverse events in a mass smallpox vaccination campaign. Effect Clin Pract. 2002, 5: 84-90.
26.
go back to reference Just I, Finke H: A contribution to the stability of the MVA-vaccine. ZBL Bakt Hyg I Abt Orig. 1979, A245: 276-282. Just I, Finke H: A contribution to the stability of the MVA-vaccine. ZBL Bakt Hyg I Abt Orig. 1979, A245: 276-282.
27.
go back to reference Newman FK, Frey SE, Blevins TP, Yan L, Belshe RB: Stability of undiluted and diluted vaccinia-virus vaccine, Dryvax. J Infect Dis. 2003, 187 (8): 1318-1322. 10.1086/374564.CrossRef Newman FK, Frey SE, Blevins TP, Yan L, Belshe RB: Stability of undiluted and diluted vaccinia-virus vaccine, Dryvax. J Infect Dis. 2003, 187 (8): 1318-1322. 10.1086/374564.CrossRef
28.
go back to reference Kline RL, Regnery RL, Armstrong GL, Damon IK: Stability of diluted smallpox vaccine under simulated clinical conditions. Vaccine. 2005, 23 (41): 4944-4946. 10.1016/j.vaccine.2005.05.016.CrossRefPubMed Kline RL, Regnery RL, Armstrong GL, Damon IK: Stability of diluted smallpox vaccine under simulated clinical conditions. Vaccine. 2005, 23 (41): 4944-4946. 10.1016/j.vaccine.2005.05.016.CrossRefPubMed
29.
go back to reference Lee KN, Hutson CL, Kline R, Curns AT, Dougherty C, Allen C, Damon I, Regnery R: Smallpox vaccine stability after maintenance at temperatures not recommended for shipping. Vaccine. 2006, 24 (7): 884-886. 10.1016/j.vaccine.2005.08.079.CrossRefPubMed Lee KN, Hutson CL, Kline R, Curns AT, Dougherty C, Allen C, Damon I, Regnery R: Smallpox vaccine stability after maintenance at temperatures not recommended for shipping. Vaccine. 2006, 24 (7): 884-886. 10.1016/j.vaccine.2005.08.079.CrossRefPubMed
Metadata
Title
Can vaccinia virus be replaced by MVA virus for testing virucidal activity of chemical disinfectants?
Authors
Holger F Rabenau
Ingrid Rapp
Jochen Steinmann
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2010
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-10-185

Other articles of this Issue 1/2010

BMC Infectious Diseases 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine